OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis
Lorenz Lehmann, Markus Heckmann, Guillaume Bailly, et al.
Circulation (2023) Vol. 148, Iss. 6, pp. 473-486
Closed Access | Times Cited: 70
Lorenz Lehmann, Markus Heckmann, Guillaume Bailly, et al.
Circulation (2023) Vol. 148, Iss. 6, pp. 473-486
Closed Access | Times Cited: 70
Showing 1-25 of 70 citing articles:
Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective
Paul Gougis, Floriane Jochum, Baptiste Abbar, et al.
EClinicalMedicine (2024) Vol. 70, pp. 102536-102536
Open Access | Times Cited: 37
Paul Gougis, Floriane Jochum, Baptiste Abbar, et al.
EClinicalMedicine (2024) Vol. 70, pp. 102536-102536
Open Access | Times Cited: 37
Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence
Nabil V. Sayour, Ágnes Paál, Pietro Ameri, et al.
European Heart Journal (2024) Vol. 45, Iss. 14, pp. 1224-1240
Open Access | Times Cited: 19
Nabil V. Sayour, Ágnes Paál, Pietro Ameri, et al.
European Heart Journal (2024) Vol. 45, Iss. 14, pp. 1224-1240
Open Access | Times Cited: 19
Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure
Tamás G. Gergely, Zsófia D. Drobni, Marinos Kallikourdis, et al.
Nature Reviews Cardiology (2024) Vol. 21, Iss. 7, pp. 443-462
Closed Access | Times Cited: 16
Tamás G. Gergely, Zsófia D. Drobni, Marinos Kallikourdis, et al.
Nature Reviews Cardiology (2024) Vol. 21, Iss. 7, pp. 443-462
Closed Access | Times Cited: 16
Cardiotoxicity and peri‐operative considerations in immune checkpoint inhibitor and chimeric antigen receptor T‐cell therapy: a narrative review
Aishwarya Malode, Bhargav Makwana, Vahin Patel, et al.
Anaesthesia (2025)
Closed Access | Times Cited: 2
Aishwarya Malode, Bhargav Makwana, Vahin Patel, et al.
Anaesthesia (2025)
Closed Access | Times Cited: 2
Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis
Charlotte Fenioux, Baptiste Abbar, Samia Boussouar, et al.
Nature Medicine (2023) Vol. 29, Iss. 12, pp. 3100-3110
Closed Access | Times Cited: 39
Charlotte Fenioux, Baptiste Abbar, Samia Boussouar, et al.
Nature Medicine (2023) Vol. 29, Iss. 12, pp. 3100-3110
Closed Access | Times Cited: 39
Cardiovascular toxicities of immune therapies for cancer – a scientific statement of the Heart Failure Association (HFA ) of the ESC and the ESC Council of Cardio‐Oncology
Carlo G. Tocchetti, Dimitrios Farmakis, Yvonne Koop, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 10, pp. 2055-2076
Closed Access | Times Cited: 15
Carlo G. Tocchetti, Dimitrios Farmakis, Yvonne Koop, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 10, pp. 2055-2076
Closed Access | Times Cited: 15
Cardiac Troponin in Patients With Light Chain and Transthyretin Cardiac Amyloidosis
Laura De Michieli, Alberto Cipriani, Sabino Iliceto, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 1, pp. 1-15
Open Access | Times Cited: 13
Laura De Michieli, Alberto Cipriani, Sabino Iliceto, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 1, pp. 1-15
Open Access | Times Cited: 13
Cardiovascular toxicity of immune therapies for cancer
Nicolas L. Palaskas, Hyeon-Ju Ali, Efstratios Koutroumpakis, et al.
BMJ (2024), pp. e075859-e075859
Closed Access | Times Cited: 10
Nicolas L. Palaskas, Hyeon-Ju Ali, Efstratios Koutroumpakis, et al.
BMJ (2024), pp. e075859-e075859
Closed Access | Times Cited: 10
Autoimmune Myocarditis, Old Dogs and New Tricks
Taejoon Won, E Song, Hannah M. Kalinoski, et al.
Circulation Research (2024) Vol. 134, Iss. 12, pp. 1767-1790
Open Access | Times Cited: 10
Taejoon Won, E Song, Hannah M. Kalinoski, et al.
Circulation Research (2024) Vol. 134, Iss. 12, pp. 1767-1790
Open Access | Times Cited: 10
Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors
Tamás G. Gergely, Zsófia D. Drobni, Nabil V. Sayour, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 9
Tamás G. Gergely, Zsófia D. Drobni, Nabil V. Sayour, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 9
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart
Amir Munir, Alan Gutierrez, Juan Qin, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 8, pp. 540-553
Closed Access | Times Cited: 8
Amir Munir, Alan Gutierrez, Juan Qin, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 8, pp. 540-553
Closed Access | Times Cited: 8
2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis
Mark H. Drazner, Biykem Bozkurt, Leslie T. Cooper, et al.
Journal of the American College of Cardiology (2024)
Closed Access | Times Cited: 8
Mark H. Drazner, Biykem Bozkurt, Leslie T. Cooper, et al.
Journal of the American College of Cardiology (2024)
Closed Access | Times Cited: 8
Immune Checkpoint Inhibitor–Related Myocarditis With or Without Concomitant Myopathy
Osnat Itzhaki Ben Zadok, Méabh O’Hare, Anju Nohria
JACC CardioOncology (2025)
Open Access | Times Cited: 1
Osnat Itzhaki Ben Zadok, Méabh O’Hare, Anju Nohria
JACC CardioOncology (2025)
Open Access | Times Cited: 1
Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction
Yen-Chou Chen, Charles Dolladille, Anjali Rao, et al.
JACC CardioOncology (2025) Vol. 7, Iss. 3, pp. 234-248
Open Access | Times Cited: 1
Yen-Chou Chen, Charles Dolladille, Anjali Rao, et al.
JACC CardioOncology (2025) Vol. 7, Iss. 3, pp. 234-248
Open Access | Times Cited: 1
Cardiac Troponin I and T in ICI Myocarditis Screening, Diagnosis, and Prognosis
Ana Barac, Raymond Wadlow, John F. Deeken, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 5, pp. 804-807
Open Access | Times Cited: 8
Ana Barac, Raymond Wadlow, John F. Deeken, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 5, pp. 804-807
Open Access | Times Cited: 8
Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study
Felix Korell, Lukas Entenmann, Sebastian Welf Romann, et al.
EClinicalMedicine (2024) Vol. 69, pp. 102504-102504
Open Access | Times Cited: 7
Felix Korell, Lukas Entenmann, Sebastian Welf Romann, et al.
EClinicalMedicine (2024) Vol. 69, pp. 102504-102504
Open Access | Times Cited: 7
Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation
Si-Jia Sun, Xiao‐Dong Jiao, Zhigang Chen, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Si-Jia Sun, Xiao‐Dong Jiao, Zhigang Chen, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach
Gillian Murtagh, Christopher R. deFilippi, Qiong Zhao, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 6
Gillian Murtagh, Christopher R. deFilippi, Qiong Zhao, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 6
Circulating Cardiovascular Biomarkers in Cancer Therapeutics‐Related Cardiotoxicity: Review of Critical Challenges, Solutions, and Future Directions
Gillian Murtagh, James L. Januzzi, Marielle Scherrer‐Crosbie, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 21
Open Access | Times Cited: 13
Gillian Murtagh, James L. Januzzi, Marielle Scherrer‐Crosbie, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 21
Open Access | Times Cited: 13
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity
Ying Wang, Carolin Ertl, Christina Schmitt, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 4
Ying Wang, Carolin Ertl, Christina Schmitt, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 4
Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments
Simon Travers, Joachim Alexandre, Lauren A. Baldassarre, et al.
Archives of cardiovascular diseases (2025)
Closed Access
Simon Travers, Joachim Alexandre, Lauren A. Baldassarre, et al.
Archives of cardiovascular diseases (2025)
Closed Access
Biomarkers for cancer therapy-related cardiovascular toxicity
Jiaxin Song, Shuqin Liu, Xiaohui Shi, et al.
International review of cell and molecular biology (2025)
Closed Access
Jiaxin Song, Shuqin Liu, Xiaohui Shi, et al.
International review of cell and molecular biology (2025)
Closed Access
Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review
Xiuyue Man, Hong Wang, Chen Chen, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Xiuyue Man, Hong Wang, Chen Chen, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Real life management of elevated troponin in patients treated with immune checkpoint inhibitors
Lior Zornitzki, Dana Viskin, Ophir Freund, et al.
CJC Open (2025)
Open Access
Lior Zornitzki, Dana Viskin, Ophir Freund, et al.
CJC Open (2025)
Open Access
Artificial Intelligence to Enhance Precision Medicine in Cardio-Oncology: A Scientific Statement From the American Heart Association
Rohan Khera, Aarti Asnani, Jacob Krive, et al.
Circulation Genomic and Precision Medicine (2025)
Closed Access
Rohan Khera, Aarti Asnani, Jacob Krive, et al.
Circulation Genomic and Precision Medicine (2025)
Closed Access
